About the Authors
- Colton Linnertz
-
Affiliation Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina, United States of America
- Ann M. Saunders
-
Affiliations Deane Drug Discovery Institute, Duke University Medical Center, Durham, North Carolina, United States of America, Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America
- Michael W. Lutz
-
Affiliation Deane Drug Discovery Institute, Duke University Medical Center, Durham, North Carolina, United States of America
- Donna M. Crenshaw
-
Affiliation Deane Drug Discovery Institute, Duke University Medical Center, Durham, North Carolina, United States of America
- Iris Grossman
-
Affiliation Cabernet Pharmaceuticals, Chapel Hill, North Carolina, United States of America
- Daniel K. Burns
-
Affiliation Cabernet Pharmaceuticals, Chapel Hill, North Carolina, United States of America
- Keith E. Whitfield
-
Affiliation Department of Psychology and Neuroscience, Duke University, Durham, North Carolina, United States of America
- Michael A. Hauser
-
Affiliation Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States of America
- Jeanette J. McCarthy
-
Affiliation Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina, United States of America
- Megan Ulmer
-
Affiliation Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States of America
- Rand Allingham
-
Affiliation Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States of America
- Kathleen A. Welsh-Bohmer
-
Affiliations Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University, Durham, North Carolina, United States of America, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina, United States of America
- Allen D. Roses
-
Affiliations Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina, United States of America, Deane Drug Discovery Institute, Duke University Medical Center, Durham, North Carolina, United States of America, Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America, Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University, Durham, North Carolina, United States of America
- Ornit Chiba-Falek
-
* E-mail: o.chibafalek@duke.edu
Affiliations Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina, United States of America, Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America, Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University, Durham, North Carolina, United States of America
Competing Interests
ADR is the CEO of Cabernet Pharmaceuticals, Inc., a pipeline pharmacogenetics consultation and project management company; and CEO of Zinfandel Pharmaceuticals, Inc., who is in an alliance with Takeda Pharmaceuticals to perform a delay of onset trial for dementias of the Alzheimer type. AMS, MWL and DMC are Members of the Joint Biomarker Committee for the Zinfandel-Takeda Alliance clinical trial and AMS is the spouse of ADR. DKB is a Senior VP of Zinfandel Pharmaceuticals. International Application No: PCT/US2009/053373: Method of identifying disease risk factors. Assignee: Zinfandel Pharmaceuticals, Inc; Inventor: Allen D. Roses. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: AMS ADR OC-F. Performed the experiments: CL. Analyzed the data: AMS MWL DMC IG DKB ADR OC-F. Contributed reagents/materials/analysis tools: KEW MAH JJM MU RA KAW-B OC-F. Wrote the paper: AMS MWL DMC ADR OC-F.